ThirdLaw Molecular Inc.

ThirdLaw Molecular is a targeted drug discovery company that is reimagining molecular therapeutics by pioneering the development of Spiroligomer™ technology. This is a novel, patent-protected chemical platform of synthetic, modular, fused-ring structures incorporating a diverse range of functional groups, allowing exquisite control of molecular shapes. The Company is designing and synthesizing searchable libraries of billions of these unique, chemically distinctive, compounds for highly selective binding of proteins of biologic interest – including those previously considered undruggable. Spiroligomer™-based molecules offer selectivity, cell permeability, oral bioavailability, protease resistance, and scalable synthesis. Combined with ThirdLaw Molecular’s computational design expertise, they represent a promising source of safe, effective therapeutics, both for partnerships and the Company’s pipeline.